Dr. Vijaypal Reddy

Dr. Vijayapal Reddy

  • Head of Cancer Non-Clinical Safety Assessment at Eli Lilly and Company based in United States
  • As a Director/President of Vipra LLC, a pharmaceutical consulting company, he provides strategic scientific input and direction in several disease areas including cancer.
  • Nearly 30 years of experience in the global drug discovery and development industry, which includes over 22 years with Eli Lilly and Company
  • During his tenure at Lilly, he was a critical contributor in delivering nonclinical toxicology packages to support first in human studies (INDs) for many drug candidates and successfully submitted two NDAs (Evista, Alimta) and two BLAs (Cyramza and Lartruvo).
  • PhD from Utah State University and postdoctoral fellowship at the University of Nebraska Medical Center